150 Milligrams 2016

Sidse Babett Knudsen stars as Dr. Irène Frachon, a pulmonologist at a university hospital in Brest, in northern France. The film opens in a high-stakes medical setting, where surgeons perform open-heart procedures, immediately signaling the life-and-death rhythm of modern medicine. Frachon begins to notice a troubling pattern: Corinne Zacharria, Isabelle de Hertogh—a patient she treats—shows severely damaged heart valves, a condition appearing across several patients who have taken Mediator, a drug developed by Servier for diabetes and weight loss. The scenes in the hospital ward set a meticulous, patient-centered tone, and Frachon’s sharp clinical eye drives the investigation from the very first diagnosis.

Driven by what she sees in the clinic, Frachon pursues a broader answer: is Mediator really behind these serious heart problems? She pursues epidemiological evidence, gathering data, and assembling a network of colleagues who share her concern. Among them, Dr. Antoine Le Bihan, Benoît Magimel, emerges as a crucial ally, bringing rigorous research methods and a steady voice to the growing case. Together, they begin to connect isolated medical anomalies into a coherent pattern, translating bedside worry into bedside science. Their collaboration deepens as the data accumulate, reinforcing Frachon’s hypothesis in a way that cannot be dismissed.

When the team presents their findings to AFSSAPS, the regulatory body responsible for health products in France, they encounter stiff scrutiny from Servier’s representatives. The film lays bare the friction between patient safety and corporate interests, a tension that complicates the path to a decisive warning. Despite clear signals from the data, the regulators are reluctant to remove Mediator from the market, and the initial push to pull the drug proves difficult. The procedural drama—filled with expert testimony, subtle political maneuvering, and the sting of corporate pushback—filters through Frachon’s circle and colors every interaction with regulators, clinicians, and patients alike. The sense of persistence and moral urgency remains front and center, even as obstacles mount.

Unbowed, Frachon presses forward beyond the confines of the hospital. She publicly records the journey through a self-published book detailing the research and the stories behind the cases, hoping to empower patients and alert the broader health community. Servier fights back against the publication, elevating the stakes and broadening the public conversation around drug safety. The effort garners support from a diverse network: journalist Anne Jouan, Lara Neumann of Le Figaro, who helps bring crucial attention to the case; AFSSAPS member Dr Catherine Haynes, Myriam Azencot; and a CNAM informant who provides essential data that helps triangulate the findings. This coalition—comprising clinicians, journalists, regulators, and insiders—gives Frachon a human-centered, multi-perspective vantage on the fight for accountability.

As the investigative drumbeat continues, the film foregrounds the human costs of delay: the months and years of effort behind each datapoint, the strain on Frachon’s family, and the mounting pressure to prove a link that could alter regulatory and corporate futures. Against this backdrop, the mortar of the narrative remains the stark statistic that emerges from the investigation: Mediator is linked to around 500 deaths, most of them among women. The scope of the tragedy sharpens Frachon’s resolve and reframes the discourse on drug safety, shifting the story from a personal crusade to a public health imperative.

In the end, the movie does more than recount a battle between a clinician and a pharmaceutical giant. It dramatizes a systemic struggle—between patient welfare and market forces, between precaution and speed, between individual courage and institutional inertia. The outcome is not wrapped in a neat verdict, but the film leaves a lasting impression about the importance of independent inquiry, rigorous science, and transparent regulation. It honors the tireless work of those who seek the truth despite formidable resistance, and it invites viewers to consider how many lives depend on the integrity of medical oversight and the responsible stewardship of new therapies.

The story is anchored by a constellation of performances that ground the emotional impact in real-world gravity. Benoît Magimel brings a steady, methodical counterpoint to Frachon’s relentless drive, while Philippe Uchan embodies the calculated pressure of corporate messaging. The cast surrounding Frachon—Myriam Azencot as Catherine Haynes, Lara Neumann as Anne Jouan, and Gilles Treton as Dr Yannick Jobic—helps to illuminate the wide network of professionals and stakeholders who shape the course of events. The film’s visual language—clinical detail, documentary pacing, and restrained emotional arousal—keeps the focus on evidence, consequence, and the human story behind every statistic. In this way, it not only reports a medical saga but also invites viewers to reflect on how society answers the question of risk, responsibility, and reform in the pharmaceutical era.